Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?

References

• Cancer burden statistics and trends across Europe [Internet]. [cited 2022 Mar 13]. p. https://ecis.jrc.ec.europa.eu/. Available from://ecis.jrc.ec.europa.eu.
   Google Scholar
• Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530–2540.
   PubMed Web of Science ®Google Scholar
• Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794–5799.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–1290.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116–1127.
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha S-Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384:1289–1300.
   PubMed Web of Science ®Google Scholar
• Tran J, Ornstein MC. Clinical review on the management of metastatic renal cell carcinoma. JCO Oncol Pract. 2022;18:187–196.
   PubMedGoogle Scholar
• Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384:829–841.
   PubMed Web of Science ®Google Scholar
• Nocera L, Karakiewicz PI, Wenzel M, et al. Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis. J Urol. 2022;207:16–24.
   PubMedGoogle Scholar
• Powles T, Albiges L, Bex A, et al. ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32:1511–1519. InternetAvailable from. DOI:10.1016/j.annonc.2021.09.014.
   PubMed Web of Science ®Google Scholar
• Stellato M, Santini D. Metastatic renal cell carcinoma classified as good risk: the easiest choice has become the hardest. Chemotherapy. 2021;66(5–6):196–198.
   PubMedGoogle Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: eSMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:706–720.
   PubMed Web of Science ®Google Scholar
• Kalra S, Rini BI, Jonasch E. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. Ann Oncol. 2015;26:1300–1304. InternetAvailable from. DOI:10.1093/annonc/mdv030.
   PubMed Web of Science ®Google Scholar
• Barrios CH, Hernandez-Barajas D, Brown MP, et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer. 2012;118:1252–1259.
   PubMed Web of Science ®Google Scholar
• Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27:4068–4075.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012;30:1371–1377.
   PubMed Web of Science ®Google Scholar
• Krens SD, van Erp NP, Groenland SL, et al. Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer. BMC Cancer. 2022;22:1–12. InternetAvailable from. DOI:10.1186/s12885-022-09338-1.
   PubMedGoogle Scholar
• Noda S, Yoshida T, Hira D, et al. Exploratory investigation of target pazopanib concentration range for patients with renal cell carcinoma. Clin Genitourin Cancer. 2019;17:e306–313. InternetAvailable from. DOI:10.1016/j.clgc.2018.12.001.
   PubMedGoogle Scholar
• Iacovelli R, Cossu Rocca M, Galli L, et al. Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. Urol Oncol Semin Orig Investig. 2017;35. Internet541.e7541.e13Available from. Internet541.e7541.e13Available from. DOI:10.1016/j.urolonc.2017.05.007
   PubMedGoogle Scholar
• Teo YL, Chue XP, Chau NM, et al. Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. Target Oncol. 2015;10:429–437.
   PubMed Web of Science ®Google Scholar
• Castellano D, Pablo Maroto J, Benzaghou F, et al. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: implications for patient care. Cancer Treat Rev [Internet]. 2020;89:102062. Available from. DOI:10.1016/j.ctrv.2020.102062.
   PubMedGoogle Scholar
• Verheijen RB, Bins S, Mathijssen RHJ, et al. Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clin Cancer Res. 2016;22:5738–5746.
   PubMed Web of Science ®Google Scholar
• Hermansen CK, Donskov F. Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: older patients more prone to toxicity. J Geriatr Oncol. 2021;12:827–833. InternetAvailable from. DOI:10.1016/j.jgo.2020.12.008.
   PubMedGoogle Scholar
• Henriksen JN, Bøttger P, Hermansen CK, et al. Pazopanib-induced liver toxicity in patients with metastatic renal cell carcinoma: effect of UGT1A1 polymorphism on pazopanib dose reduction, safety, and patient outcomes. Clin Genitourin Cancer. 2020;18:62–68.e2. InternetAvailable from. DOI:10.1016/j.clgc.2019.09.013.
   PubMed Web of Science ®Google Scholar
• De Sijpe G V, Beuselinck B, Van Nieuwenhuyse T, et al. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol. 2020;76:1273–1280.
   PubMedGoogle Scholar
• Lacy S, Nielsen J, Yang B, et al. Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2018;81:1061–1070. InternetAvailable from. DOI:10.1007/s00280-018-3579-7.
   PubMed Web of Science ®Google Scholar
• Schwartz LH, Litière S, De VE, et al. Update and clarification: From the RECIST Committees. Eur J Cancer. 2016;62:132–137.
   Google Scholar
• Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66:357–371.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;11(356):115–124.
   Google Scholar
• Buti S, Donini M, Bersanelli M, et al. Feasibility, safety, and efficacy of an alternative schedule of sunitinib for the treatment of patients with metastatic renal cell carcinoma: a retrospective study. Drugs R D. 2017;17:585–596.
   PubMedGoogle Scholar
• Atkinson BJ, Kalra S, Wang X, et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014;191:611–618.
   PubMed Web of Science ®Google Scholar
• Bjarnason GA, Khalil B, Hudson JM, et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol Semin Orig Investig. 2014;32:480–487. InternetAvailable from. DOI:10.1016/j.urolonc.2013.10.004.
   PubMed Web of Science ®Google Scholar
• Kang HJ, Lee S. Tolerability of alternative dosing schedules for sunitinib: a systematic review and meta-analysis. Yonsei Med J. 2020;61:837–843.
   PubMedGoogle Scholar
• Westerdijk K, Krens SD, van der Graaf WTA, et al. The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour. Br J Clin Pharmacol. 2021;87:326–335.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35:591–597.
   PubMed Web of Science ®Google Scholar
• Albiges L, Fléchon A, Chevreau C, et al. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: results from the CABOREAL early access program. Eur J Cancer. 2021;142:102–111.
   PubMedGoogle Scholar
• Gan CL, Dudani S, Wells JC, et al. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: results from the International metastatic renal cell carcinoma database consortium. Cancer Med. 2021;10:1212–1221.
   PubMedGoogle Scholar
• Cerbone L, Combarel D, Geraud A, et al. $3$2 Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open. 2021;6:100312. InternetAvailable from. DOI:10.1016/j.esmoop.2021.100312.
   PubMedGoogle Scholar
• Banna GL, Collovà E, Gebbia V, et al. $3$2 Anticancer oral therapy: emerging related issues. Cancer Treat Rev [Internet]. 2010;36:595–605. Available from. DOI:10.1016/j.ctrv.2010.04.005.
   PubMed Web of Science ®Google Scholar
• Gebbia V, Bellavia M, Banna GL, et al. Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer. Clin Lung Cancer. 2013;14:390–398. InternetAvailable from. DOI:10.1016/j.cllc.2012.11.007.
   PubMed Web of Science ®Google Scholar
• Rescigno P, Maruzzo M, Rebuzzi SE, et al. Adherence to oral treatments in elderly patients with advanced prostate cancer: the ADHERE study, a prospective trial of the meet-URO network. J Clin Oncol. 2022;40:12044.
   Google Scholar